Clinical Trials | September 05, 2025
AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension
The medicine was well tolerated, with no unexpected safety issue
The medicine was well tolerated, with no unexpected safety issue
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
The three-day expo will feature an expansive exhibition showcasing MSMEs, startups, research institutions, future innovation pavilions, state showcases, and government initiatives
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
Subscribe To Our Newsletter & Stay Updated
